

**Asahi Kasei Corporation**

Head Office: 3-3-23 Nakanoshima, Kita-ku, Osaka, Japan

Tokyo Head Office: 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan

Security code: 3407

Contact: Corporate Communications, Phone +81-3-3296-3008, Fax +81-3-3296-3162

May 10, 2010

**Consolidated Results for Fiscal Year 2009:  
April 1, 2009 – March 31, 2010**

(All figures in millions of yen, rounded to the nearest million, unless otherwise specified)

**I. Summary of Consolidated Results**

## 1. Operating results (percent change from previous year in brackets)

	FY 2009	FY 2008
Net sales	1,433,595 [-7.7%]	1,553,108 [-8.5%]
Operating income	57,622 [+64.8%]	34,959 [-72.6%]
Ordinary income	56,367 [+73.4%]	32,500 [-73.0%]
Net income	25,286 [+433.0%]	4,745 [-93.2%]
Net income per share*	18.08	3.39
Diluted net income per share*	—	—
Net income/shareholders' equity	4.1%	0.7%
Ordinary income/total assets	4.1%	2.3%
Operating income/net sales	4.0%	2.3%

\* Yen

Note:

Equity in earnings of affiliates—

¥1,151 million during fiscal 2009, ¥831 million during fiscal 2008.

## 2. Financial position

At fiscal year end, March	2010	2009
Total assets	1,368,892	1,379,337
Net assets	644,688	611,351
Net worth/total assets	46.3%	43.8%
Net worth per share*	452.91	431.77

\* Yen

Note:

- Net worth consists of shareholders' equity and valuation, translation adjustments and others.
- Net worth as of March 31, 2010, was ¥633,343 million; as of March 31, 2009, ¥603,846 million.

## 3. Cash flows

	FY 2009	FY 2008
Cash flows from operating activities	169,308	68,812
Cash flows from investing activities	(100,185)	(135,707)
Cash flows from financing activities	(75,071)	87,314
Cash and cash equivalents at end of period	93,125	98,092

## II. Cash Dividends

Fiscal year	Cash dividends per share*					Total annual dividend amount	Dividends/consolidated net income	Dividends/consolidated net worth
	Q1	Q2	Q3	Q4	Total annual			
2008	—	7.00	—	3.00	10.00	13,986	295.0%	2.2%
2009	—	5.00	—	5.00	10.00	13,984	55.3%	2.2%
2010 (forecast)	—	5.00	—	5.00	10.00		32.9%	

\* Yen

## III. Forecast for Fiscal 2010 (April 1, 2010 – March 31, 2011)

(percent change from same period of previous year in brackets)

	For Q1–Q2	For the fiscal year
Net sales	792,000 [+20.2%]	1,677,000 [+17.0%]
Operating income	31,500 [+75.4%]	80,000 [+38.8%]
Ordinary income	31,000 [+105.6%]	77,500 [+37.5%]
Net income	13,000 [+206.5%]	42,500 [+68.1%]
Net income per share*	9.30	30.39

\*Yen

Note:

Performance forecasts are based on the best information available at this time, but actual results may diverge from these forecasts due to a variety of factors which cannot be foreseen.

## IV. Other Information

- Changes in significant subsidiaries which affected scope of consolidation during the fiscal year: None.
- Significant changes in the basis for preparation of consolidated financial statements: Yes.

- Application of Partial Amendments to Accounting Standard for Retirement Benefits (Part 3)

Partial Amendments to Accounting Standard for Retirement Benefits (Part 3) (ASBJ Statement No. 19, July 31, 2008) is applied beginning with the fiscal year ended March 31, 2010. This has no effect on operating income, ordinary income, or income before income taxes.

- Application of Accounting Standard for Construction Contracts

Accounting Standard for Construction Contracts (ASBJ Statement No. 15, December 27, 2007) and Guidance on Accounting Standard for Construction Contracts (ASBJ Guidance No. 18, December 27, 2007) are applied beginning with the fiscal year ended March 31, 2010. For construction contracts commencing during the fiscal year ended March 31, 2010, and thereafter, the percentage-of-completion method is applied to the portion completed by March 31, 2010, for which the outcome of the construction activity is deemed certain (progress of work estimated by percentage of cost incurred) and the completed-contract method is applied to other work. This change has no effect on the consolidated financial statements.

### 3. Additional information

Consolidated subsidiary Asahi Kasei Pharma Corp. had sought compensation from CoTherix, Inc. of the US for breach of the terms of a license agreement for fasudil rho-kinase inhibitor, and in December 2009 a final arbitration ruling was issued. Deducting expenses incurred in the arbitration proceedings, etc., from the arbitration award received by Asahi Kasei Pharma, ¥6,502 million is recorded in the consolidated statements of income as “gain on arbitration award” under extraordinary income.

### 4. Number of shares outstanding

Fiscal year ended March	2010	2009
Number of shares outstanding at end of period	1,402,616,332	1,402,616,332
Number of shares of treasury stock at end of period	4,228,468	4,070,731

## V. Summary of Non-Consolidated Results

### 1. Results for fiscal 2009 (April 1, 2009 – March 31, 2010)

#### (1) Operating results (percent change from previous year in brackets)

	FY 2009	FY 2008
Revenue	17,034 [-45.9%]	31,470 [-37.0%]
Operating income	3,204 [-80.9%]	16,745 [-50.5%]
Ordinary income	4,643 [-74.5%]	18,213 [-47.5%]
Net income	6,502 [-62.3%]	17,237 [-54.8%]
Net income per share*	4.65	12.32
Diluted net income per share*	—	—

\* Yen

#### (2) Financial position

At fiscal year end, March	2010	2009
Total assets	718,645	775,811
Net assets	388,195	385,197
Net worth/total assets	54.0%	49.6%
Net worth per share*	277.60	275.43

\* Yen

### 2. Forecast for fiscal 2010 (April 1, 2010 – March 31, 2011)

#### (percent change from same period of previous year in brackets)

	For Q1–Q2	For the fiscal year
Revenue	11,500 [+0.3%]	23,500 [+38.0%]
Operating income	3,500 [-33.5%]	8,000 [+149.7%]
Ordinary income	4,000 [-33.3%]	8,500 [+83.1%]
Net income	5,000 [-29.5%]	10,500 [+61.5%]
Net income per share*	3.58	7.51

\* Yen

Note:

Performance forecasts are based on the best information available at this time, but actual results may diverge from these forecasts due to a variety of factors which cannot be foreseen.

## VI. Overview of Consolidated Results

### 1. Consolidated group results

The global economy was generally recovering during the year, led by growth in China and other emerging countries, as an effect of economic stimulus packages implemented in response to the 2008 financial crisis. Although corporate earnings improved with increased exports to Asian countries, the Japanese economy remained sluggish as the strong yen, curtailed domestic capital investment, and weak consumer spending continued.

Although exports were on a recovery path, the operating environment for Asahi Kasei Corp. and its consolidated subsidiaries and equity-method affiliates (the Asahi Kasei Group) remained challenging due to the strong yen and a sluggish recovery of domestic demand.

Asahi Kasei's consolidated net sales for the year were ¥1,433.6 billion, decreasing by ¥119.5 billion (7.7%) from a year ago with lower market prices in the Chemicals segment during the first half of the fiscal year as an effect of decreased feedstock prices as well as the decrease in deliveries of order-built unit homes in the Homes segment. Operating income nevertheless increased by ¥22.7 billion (64.8%) from a year ago to ¥57.6 billion, driven largely by favorable performance in the Chemicals segment with improved terms of trade and in the Homes segment with the effect of operating cost reductions. Ordinary income increased by ¥23.9 billion (73.4%) from a year ago to ¥56.4 billion. Net income increased by ¥20.5 billion (433.0%) to ¥25.3 billion, including extraordinary income from a final ruling on arbitration with CoTherix, Inc. of the US recorded in the Health Care segment.

### 2. Results by operating segment

Consolidated sales and operating income by segment are shown below. Six operating segments correspond to the main fields of business, and the Services, Engineering and Others segment comprises the remainder of operations. The following segment names have been revised beginning with the first quarter of fiscal 2009 for greater clarity and correspondence with the fields of businesses under operation.

<i>Previously</i>	<i>Changed to</i>
Electronics Materials & Devices segment	Electronics segment
Pharma segment	Health Care segment

The electronic materials operations of Asahi Kasei Corp., Asahi Kasei Chemicals, and Asahi Kasei EMD (renamed Asahi Kasei Microdevices on April 1, 2009) were transferred to Asahi Kasei E-materials on April 1, 2009. In consideration of the similarity of product types and characteristics to those of electronics operations, the operations of Asahi Kasei E-materials are reported in the Electronics segment. For comparison purposes, results for the previous year have been revised to reflect the transfer of the corresponding operations from the Chemicals segment and Corporate Expenses to the Electronics segment.

The Leona™ nylon 66 filament business of Asahi Kasei Chemicals was transferred to Asahi Kasei Fibers on April 1, 2009. For comparison purposes, results for the previous year in the Chemicals and Fibers segments have been revised to reflect this transfer.

#### CHEMICALS

Sales decreased by ¥67.2 billion (9.8%) from a year ago to ¥622.1 billion and operating income increased by ¥32.6 billion to ¥26.1 billion.

Although market prices remained low during the first half of the fiscal year, operating income from chemicals and derivative products increased with recovering demand in China and other Asian markets in the second half of the fiscal year resulting in high overseas market prices for acrylonitrile (AN) and adipic acid and with a decrease in inventory valuation loss. Operating income from polymer products was flat, as low market prices due to decreased feedstock prices were offset by an increase in shipment volumes reflecting a recovery of demand in automobile and electronics applications in the second half of the fiscal year together with a decrease in inventory valuation loss. Although recovery in water-

treatment related business was sluggish and ion-exchange membrane related business was impacted by the strong yen, operating income from specialty products increased with strong performance both in home-use products such as Saran Wrap™ and in coating materials and with steady performance in functional additives.

#### HOMES

Sales decreased by ¥20.2 billion (4.9%) from a year ago to ¥389.7 billion and operating income increased by ¥3.5 billion (15.9%) to ¥25.3 billion.

Operating income from order-built and pre-built homes increased with cost reductions and other measures to heighten operating efficiency offsetting a substantial decline in deliveries of order-built Hebel Haus™ unit homes. Orders for order-built homes received during the year increased to ¥306.9 billion, up by ¥15.8 billion from a year ago, reflecting a recovery in orders during the second half of the fiscal year.

Despite steady performance in remodeling and real estate operations, operating income in housing-related operations decreased with slack performance in financing operations.

#### HEALTH CARE

Sales decreased by ¥6.4 billion (5.4%) from a year ago to ¥113.2 billion and operating income decreased by ¥8.0 billion (66.8%) to ¥4.0 billion.

Although increased shipments of the Flivas™ agent for treatment of benign prostatic hyperplasia and the Elcitonin™ calcitonin formulation contributed to sales growth in pharmaceuticals operations, operating income decreased due to a decline in licensing income.

Shipment volumes of APS™ polysulfone-membrane artificial kidneys and Sepacell™ leukocyte reduction filters grew mainly in export, but operating income in device-related operations decreased with a significant impact of the strong yen on each product family and with the effect of greater capital depreciation.

#### FIBERS

Sales decreased by ¥15.2 billion (13.1%) from a year ago to ¥101.2 billion and an operating loss of ¥2.8 billion resulted as profitability decreased by ¥1.3 billion.

Overseas shipment volumes of Roica™ elastic polyurethane filament grew, but operating income decreased due to the significant impact of low market prices and the strong yen. Exports of Bemberg™ regenerated cellulose were steady overall, but operating income decreased mainly due to the strong yen. Operating income in nonwovens operations increased with growth in shipments of Lamous™ artificial suede for car seats and the effect of operating cost reductions, although shipments of spunbond decreased. Despite lower shipment volumes of Leona™ nylon 66 filament, operating income increased with declining feedstock prices and cost reductions.

#### ELECTRONICS

Sales increased by ¥13.0 billion (10.1%) from a year ago to ¥142.7 billion and operating income decreased slightly to ¥7.2 billion.

Operating income from electronic devices increased with substantial growth in shipments of LSIs in new applications outweighing a sharp impact of the strong yen. Shipments of electronic materials recovered, particularly for Hipore™ Li-ion rechargeable battery separator, but operating income decreased with the impact of falling market prices.

#### CONSTRUCTION MATERIALS

Sales decreased by ¥13.9 billion (22.8%) from a year ago to ¥47.0 billion and operating income decreased by ¥0.5 billion (28.6%) to ¥1.2 billion.

A decline in new construction starts resulted in lower shipments of Hebel™ autoclaved aerated concrete (AAC) panels and the BasePack™ earthquake-resistant column base attachment system, and operating income in building materials and housing materials operations decreased slightly.

Operating income in foundation systems operations decreased with lower shipment volumes of Eazet™ piling systems for small-scale construction and the DynaWing™ pre-cast concrete piling system featuring minimal soil disposal and high load-bearing capacity.

Although insulation materials operations were also affected by the decline in new construction starts, cost reductions enabled an increase in operating income.

#### SERVICES, ENGINEERING AND OTHERS

Sales decreased by ¥9.7 billion (35.4%) from a year ago to ¥17.6 billion and operating income decreased by ¥3.8 billion (67.6%) to ¥1.8 billion.

Operating income in engineering operations decreased as a curtailment of capital investments led to a decline in orders received.

## VII. Consolidated Financial Statements

### 1. Balance sheets

	At end of March 2009	At end of March 2010
<b>Assets</b>		
Current assets		
Cash and deposits	97,969	93,928
Notes and accounts receivable, trade	208,868	238,931
Short-term investment securities	406	985
Merchandise and finished goods	138,098	124,557
Work in progress	82,832	75,044
Raw materials and supplies	52,609	51,484
Deferred tax assets	18,444	23,106
Other	85,626	54,027
Allowance for doubtful accounts	(2,648)	(1,654)
Total current assets	682,205	660,408
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	381,725	404,974
Accumulated depreciation	(217,710)	(224,608)
Buildings and structures, net	164,014	180,366
Machinery, equipment and vehicles	1,138,427	1,169,979
Accumulated depreciation	(977,646)	(1,005,094)
Machinery, equipment and vehicles, net	160,781	164,885
Land	53,740	55,031
Lease assets	2,540	5,808
Accumulated depreciation	(227)	(1,132)
Lease assets, net	2,313	4,676
Construction in progress	44,140	27,380
Other	109,437	115,024
Accumulated depreciation	(93,155)	(99,867)
Other, net	16,282	15,158
Subtotal	441,271	447,497
Intangible assets		
Goodwill	7,449	5,927
Other	29,935	28,729
Subtotal	37,384	34,656
Investments and other assets		
Investment securities	157,091	175,059
Long-term receivables	2,670	6,074
Deferred tax assets	28,874	15,383
Other	29,993	29,962
Allowance for doubtful accounts	(151)	(147)
Subtotal	218,477	226,331
Total noncurrent assets	697,132	708,485
Total assets	1,379,337	1,368,892

	At end of March 2009	At end of March 2010
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable, trade	113,378	121,409
Short-term loans payable	100,786	93,962
Commercial paper	55,000	19,000
Current portion of bonds	20,000	—
Lease obligations	489	1,123
Income taxes payable	4,097	12,160
Accrued expenses	86,947	91,371
Advances received	40,203	37,815
Provision for repairs	1,674	8,191
Provision for product warranties	9,396	3,607
Other	55,951	46,189
<b>Total current liabilities</b>	<b>487,921</b>	<b>434,827</b>
Noncurrent liabilities		
Bonds payable	5,000	25,000
Long-term loans payable	132,474	121,921
Lease obligations	1,845	3,593
Deferred tax liabilities	4,257	7,597
Provision for retirement benefits	109,864	109,450
Provision for directors' retirement benefits	1,046	1,225
Provision for repairs	4,499	169
Long-term guarantee deposited	19,149	18,321
Other	1,931	2,101
<b>Total noncurrent liabilities</b>	<b>280,065</b>	<b>289,378</b>
<b>Total liabilities</b>	<b>767,986</b>	<b>724,204</b>
<b>Net assets</b>		
Shareholders' equity		
Capital stock	103,389	103,389
Capital surplus	79,404	79,403
Retained earnings	418,292	432,114
Treasury stock	(1,946)	(2,017)
<b>Total shareholders' equity</b>	<b>599,139</b>	<b>612,888</b>
Valuation and translation adjustments		
Valuation difference on available-for-sale securities	23,301	36,692
Deferred gains or losses on hedges	(178)	(109)
Foreign currency translation adjustment	(18,416)	(16,128)
<b>Total valuation and translation adjustments</b>	<b>4,708</b>	<b>20,455</b>
Minority interests	7,504	11,346
<b>Total net assets</b>	<b>611,351</b>	<b>644,688</b>
<b>Total liabilities and net assets</b>	<b>1,379,337</b>	<b>1,368,892</b>



## 2. Statements of income

	FY 2008	FY 2009
Net sales	1,553,108	1,433,595
Cost of sales	1,237,815	1,100,688
Gross profit	315,293	332,907
Selling, general and administrative expenses	280,333	275,285
Operating income	34,959	57,622
Non-operating income		
Interest income	1,021	1,071
Dividends income	2,594	2,276
Equity in earnings of affiliates	831	1,151
Other	4,094	3,394
Total non-operating income	8,540	7,891
Non-operating expenses		
Interest expense	4,284	3,714
Foreign exchange loss	1,359	702
Other	5,356	4,730
Total non-operating expenses	10,999	9,146
Ordinary income	32,500	56,367
Extraordinary income		
Gain on sales of investment securities	17	112
Gain on sales of noncurrent assets	524	152
Gain on change in equity	—	153
Gain on arbitration award	—	6,502
Total extraordinary income	540	6,919
Extraordinary loss		
Loss on sales of investment securities	70	—
Loss on valuation of investment securities	721	1,918
Loss on disposal of noncurrent assets	5,943	2,944
Impairment loss	343	836
Environmental expenses	1,932	1,482
Business structure improvement expenses	5,001	10,050
Total extraordinary loss	14,009	17,230
Income before income taxes	19,031	46,056
Income taxes—current	8,521	17,107
Income taxes—deferred	5,174	3,377
Total income taxes	13,695	20,483
Minority interests in income	592	286
Net income	4,745	25,286

### 3. Statements of changes in net assets

	FY 2008	FY 2009
Shareholders' equity		
Capital stock		
Balance at end of previous fiscal year	103,389	103,389
Balance at end of fiscal year	103,389	103,389
Capital surplus		
Balance at end of previous fiscal year	79,427	79,404
Changes during the fiscal year		
Disposal of treasury stock	(23)	(1)
Total changes of items during the period	(23)	(1)
Balance at end of fiscal year	79,404	79,403
Retained earnings		
Balance at end of previous fiscal year	432,246	418,292
Reversal of revaluation reserve due to unification of accounting standards at overseas subsidiaries	873	—
Changes during the fiscal year		
Dividends from surplus	(19,581)	(11,188)
Net income	4,745	25,286
Change of scope of consolidation	—	(10)
Change of scope of equity method	10	(267)
Total changes of items during the period	(14,826)	13,821
Balance at end of fiscal year	418,292	432,114
Treasury stock		
Balance at end of previous fiscal year	(2,019)	(1,946)
Changes during the fiscal year		
Purchase of treasury stock	(241)	(96)
Disposal of treasury stock	314	25
Total changes of items during the period	73	(71)
Balance at end of fiscal year	(1,946)	(2,017)
Total shareholders' equity		
Balance at end of previous fiscal year	613,042	599,139
Reversal of revaluation reserve due to unification of accounting standards at overseas subsidiaries	873	—
Changes during the fiscal year		
Dividends from surplus	(19,581)	(11,188)
Net income	4,745	25,286
Purchase of treasury stock	(241)	(96)
Disposal of treasury stock	291	24
Change of scope of consolidation	—	(10)
Change of scope of equity method	10	(267)
Total changes of items during the period	(14,777)	13,749
Balance at end of fiscal year	599,139	612,888
Valuation, translation adjustments		
Valuation difference on available-for-sale securities		
Balance at end of previous fiscal year	51,091	23,301
Changes during the fiscal year		
Net changes of items other than shareholders' equity	(27,790)	13,391
Total changes of items during the period	(27,790)	13,391
Balance at end of fiscal year	23,301	36,692

	FY 2008	FY 2009
Deferred gains or losses on hedges		
Balance at end of previous fiscal year	11	(178)
Changes during the fiscal year		
Net changes of items other than shareholders' equity	(189)	68
Total changes of items during the period	(189)	68
Balance at end of fiscal year	(178)	(109)
Revaluation surplus		
Balance at end of previous fiscal year	873	—
Reversal of revaluation reserve due to unification of accounting standards at overseas subsidiaries	(873)	—
Balance at end of fiscal year	—	—
Foreign currency translation adjustment		
Balance at end of previous fiscal year	1,226	(18,416)
Changes during the fiscal year		
Net changes of items other than shareholders' equity	(19,642)	2,287
Total changes of items during the period	(19,642)	2,287
Balance at end of fiscal year	(18,416)	(16,128)
Total valuation, translation adjustments		
Balance at end of previous fiscal year	53,201	4,708
Reversal of revaluation reserve due to unification of accounting standards at overseas subsidiaries	(873)	—
Changes during the fiscal year		
Net changes of items other than shareholders' equity	(47,621)	15,747
Total changes of items during the period	(47,621)	15,747
Balance at end of fiscal year	4,708	20,455
Minority interest		
Balance at end of previous fiscal year	7,912	7,504
Changes during the fiscal year		
Net changes of items other than shareholders' equity	(408)	3,841
Total changes of items during the period	(408)	3,841
Balance at end of fiscal year	7,504	11,346
Total net assets		
Balance at end of previous fiscal year	674,156	611,351
Changes during the fiscal year		
Dividends from surplus	(19,581)	(11,188)
Net income	4,745	25,286
Purchase of treasury stock	(241)	(96)
Disposal of treasury stock	291	24
Change of scope of consolidation	—	(10)
Change of scope of equity method	10	(267)
Net changes of items other than shareholders' equity	(48,029)	19,588
Total changes of items during the period	(62,805)	33,338
Balance at end of fiscal year	611,351	644,688

#### 4. Statements of cash flows

	FY 2008	FY 2009
Cash flows from operating activities:		
Income (loss) before income taxes	19,031	46,056
Depreciation and amortization	79,436	86,166
Impairment loss	343	836
Amortization of goodwill	619	1,089
Amortization of negative goodwill	(90)	(190)
Increase (decrease) in provision for repairs	(621)	2,187
Increase (decrease) in provision for product warranties	3,380	(5,790)
Increase (decrease) in provision for retirement benefits	(6,011)	(1,284)
Interest and dividend income	(3,615)	(3,347)
Interest expense	4,284	3,714
Equity in (earnings) losses of affiliates	(831)	(1,151)
Loss (gain) on sales of investment securities	53	(112)
Loss (gain) on valuation of investment securities	721	1,918
Loss (gain) on sales of property, plant and equipment	(524)	(152)
Loss (gain) on disposal of noncurrent assets	5,943	2,944
Gain on arbitration award	—	(6,502)
Decrease (increase) in notes and accounts receivable, trade	83,714	(25,106)
Decrease (increase) in inventories	(6,737)	33,994
Increase (decrease) in notes and accounts payable, trade	(37,272)	1,603
Increase (decrease) in accrued expenses	(21,530)	2,555
Increase (decrease) in advances received	(9,498)	(2,476)
Other, net	(18,728)	20,048
Subtotal	92,068	157,003
Interest and dividend income, received	5,925	4,418
Interest expense, paid	(4,185)	(3,758)
Proceeds from arbitration award	—	6,502
Income taxes, paid	(24,996)	5,143
Net cash provided by (used in) operating activities	68,812	169,308
Cash flows from investing activities:		
Purchase of property, plant and equipment	(97,214)	(84,482)
Proceeds from sales of property, plant and equipment	1,948	675
Purchase of intangible assets	(22,016)	(6,876)
Purchase of investment securities	(17,518)	(11,291)
Proceeds from sales of investment securities	516	5,272
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation	—	914
Payments of loans receivable	(6,374)	(12,623)
Collection of loans receivable	5,791	11,665
Other, net	(839)	(3,438)
Net cash provided by (used in) investing activities	(135,707)	(100,185)

	FY 2008	FY 2009
Cash flows from financing activities:		
Increase in short-term loans payable	81,230	7,744
Decrease in short-term loans payable	(34,439)	(9,956)
Proceeds from issuance of commercial paper	135,000	59,000
Redemption of commercial paper	(135,000)	(95,000)
Proceeds from long-term loans payable	97,131	5,633
Repayment of long-term loans payable	(11,947)	(29,863)
Proceeds from issuance of bonds	—	20,000
Redemption of bonds	(25,000)	(20,000)
Repayments of lease obligations	(206)	(908)
Purchase of treasury stock	(249)	(99)
Proceeds from disposal of treasury stock	147	24
Cash dividends paid	(19,581)	(11,188)
Cash dividends paid to minority shareholders	(352)	(342)
Other	581	(115)
Net cash provided by (used in) financing activities	87,314	(75,071)
Effect of exchange rate change on cash and cash equivalents	(5,360)	620
Net increase (decrease) in cash and cash equivalents	15,059	(5,327)
Cash and cash equivalents at beginning of period	83,033	98,092
Increase (decrease) in cash and cash equivalents resulting from change of scope of consolidation	—	360
Cash and cash equivalents at end of period	98,092	93,125

## VIII. Segment Information

### 1. Industry segments

#### (1) Fiscal 2008

	Chemicals	Homes	Pharma	Fibers	Electronics Materials & Devices	Construction Materials	Services, Engineering and Others	Combined	Corporate Expenses, Assets, and Eliminations*	Consolidated
<i>Sales</i>										
Customers	741,486	409,882	119,619	102,176	91,721	60,927	27,297	1,553,108	—	1,553,108
Intersegment	15,728	71	11	1,990	654	12,676	32,567	63,697	(63,697)	—
Total	757,214	409,952	119,630	104,166	92,375	73,603	59,864	1,616,804	(63,697)	1,553,108
Operating expenses	757,632	388,082	107,590	105,027	89,030	71,919	54,237	1,573,519	(55,370)	1,518,148
Operating income (loss)	(419)	21,871	12,040	(861)	3,345	1,683	5,627	43,286	(8,326)	34,959
<i>Identifiable assets, depreciation and amortization, impairment loss, and capital expenditure</i>										
Identifiable assets	583,614	216,716	176,699	107,781	115,154	43,736	449,637	1,693,337	(314,000)	1,379,337
Depreciation and amortization	36,666	3,439	10,275	6,440	15,428	3,619	806	76,673	2,763	79,436
Impairment loss	—	—	112	264	79	754	—	1,208	—	1,208
Capital expenditure	45,667	7,037	31,569	12,257	21,557	2,430	1,082	121,598	5,127	126,725

\* Includes corporate operating expenses of ¥14,726 million (mainly expenses for basic research and group management), and corporate assets of ¥457,979 million, such as surplus funds (cash and deposits), long-term-investment funds (investment securities, etc.), and land, etc.

Note:

Impairment losses of ¥112 million in Pharma and ¥754 million in Construction Materials are included in business structure improvement expenses.

## (2) Fiscal 2009

	Chemicals	Homes	Health Care	Fibers	Electronics	Construction Materials	Services, Engineering and Others	Combined	Corporate Expenses, Assets, and Eliminations*	Consolidated
<i>Sales</i>										
Customers	622,093	389,728	113,207	101,201	142,700	47,024	17,642	1,433,595	—	1,433,595
Intersegment	16,495	24	96	1,772	1,159	13,048	23,541	56,134	(56,134)	—
Total	638,588	389,752	113,303	102,973	143,859	60,072	41,182	1,489,729	(56,134)	1,433,595
Operating expenses	612,520	364,412	109,304	105,737	136,616	58,870	39,360	1,426,820	(50,847)	1,375,973
Operating income (loss)	26,068	25,340	3,999	(2,764)	7,243	1,202	1,822	62,909	(5,287)	57,622
<i>Identifiable assets, depreciation and amortization, impairment loss, and capital expenditure</i>										
Identifiable assets	533,296	232,031	164,161	110,426	174,131	39,981	395,449	1,649,475	(280,583)	1,368,892
Depreciation and amortization	32,416	4,309	12,191	7,719	23,594	3,263	799	84,290	2,965	87,255
Impairment loss	1,486	—	—	—	108	1,365	—	2,959	198	3,156
Capital expenditure	27,649	6,009	9,173	4,556	22,761	1,191	927	72,266	11,724	83,990

\* Includes corporate operating expenses of ¥13,831 million (mainly expenses for basic research and group management), and corporate assets of ¥404,144 million, such as surplus funds (cash and deposits), long-term-investment funds (investment securities, etc.), and land, etc.

## Note:

Impairment losses of ¥1,365 million in Construction Materials and ¥955 million in Chemicals are included in business structure improvement expenses.

## (3) Fiscal 2008, revised

For comparison purposes, fiscal 2008 results shown below are revised to reflect the April 2009 transfer of electronic materials operations from Chemicals and from Corporate Expenses, Assets, and Eliminations to Electronics and the April 2009 transfer of the Leona™ filament business from Chemicals to Fibers, as well as the revised segment names adopted in April 2009.

	Chemicals	Homes	Health Care	Fibers	Electronics	Construction Materials	Services, Engineering and Others	Combined	Corporate Expenses, Assets, and Eliminations*	Consolidated
<i>Sales</i>										
Customers	689,323	409,882	119,619	116,405	129,655	60,927	27,297	1,553,108	—	1,553,108
Intersegment	19,927	71	11	1,904	469	12,676	32,567	67,625	(67,625)	—
Total	709,250	409,952	119,630	118,309	130,124	73,603	59,864	1,620,732	(67,625)	1,553,108
Operating expenses	715,779	388,082	107,590	119,818	122,838	71,919	54,237	1,580,264	(62,116)	1,518,148
Operating income (loss)	(6,529)	21,871	12,040	(1,509)	7,286	1,683	5,627	40,469	(5,509)	34,959
<i>Identifiable assets, depreciation and amortization, impairment loss, and capital expenditure</i>										
Identifiable assets	531,724	216,716	176,699	119,889	157,551	43,736	449,637	1,695,952	(316,615)	1,379,337
Depreciation and amortization	32,245	3,439	10,275	7,156	19,828	3,619	806	77,367	2,069	79,436
Impairment loss	—	—	112	264	79	754	—	1,208	—	1,208
Capital expenditure	36,335	7,037	31,569	12,404	31,811	2,430	1,082	122,667	4,058	126,725

\* Includes corporate operating expenses of ¥11,908 million (mainly expenses for basic research and group management), and corporate assets of ¥455,318 million, such as surplus funds (cash and deposits), long-term-investment funds (investment securities, etc.), and land, etc.

## 2. Geographic information

### (1) Fiscal 2008

Segment information is not shown because over 90% of total sales were from operations domiciled in Japan and over 90% of total assets were located in Japan.

### (2) Fiscal 2009

Segment information is not shown because over 90% of total sales were from operations domiciled in Japan and over 90% of total assets were located in Japan.

## 3. Overseas sales

### (1) Fiscal 2008

	East Asia*	Other regions†	Total
Overseas sales	233,219	160,746	393,965
Consolidated net sales	—	—	1,553,108
Overseas sales/ consolidated net sales	15.0%	10.3%	25.4%

### (2) Fiscal 2009

	East Asia*	Other regions†	Total
Overseas sales	237,271	133,138	370,409
Consolidated net sales	—	—	1,433,595
Overseas sales/ consolidated net sales	16.6%	9.3%	25.8%

\* China, Korea, and Taiwan.

† Southeast Asia (except East Asia), US, Europe, and others.